^
    Back
    Association details:
    Biomarker:CDKN2A deletion
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients

    Published date:
    08/20/2020
    Excerpt:
    ...we evaluated the NGS results of 82 melanoma patients from clinical routine in 2017….we investigated their potential as a predictor for resistance to immune checkpoint inhibitors (ICI)…we find that CDKN2A deletions or loss of heterozygosity are enriched in PD (p = 0.024).
    DOI:
    https://doi.org/10.3390/cancers12092359